Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS
Reuters
Dec 08
Geron Unveils New Data Showing RYTELO Improves Outcomes in Lower-Risk MDS
Geron Corporation announced new data presented at the 67th American Society of Hematology $(ASH)$ 2025 Annual Meeting regarding its first-in-class telomerase inhibitor, RYTELO® (imetelstat). The oral and poster presentations included pooled analyses from the IMerge study population, which suggested that treatment-emergent cytopenias may be associated with clinically meaningful outcomes, such as increases in hemoglobin and transfusion independence, in patients with lower-risk myelodysplastic syndromes (MDS). Additional analyses provided insights into imetelstat's safety profile and its potential in myelofibrosis and advanced MDS/AML. The company stated that these findings support the ongoing investigation of imetelstat as a treatment option for eligible patients with lower-risk MDS. The results have already been presented and are available on Geron's website.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Geron Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9598470-en) on December 08, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.